Cargando…

Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan

Palliative care and advance care planning (ACP) from the first diagnosis of glioblastoma are important. This questionnaire survey was conducted to understand the current status of palliative care for brain tumors in Japan. Representative characteristics of Japan in comparison with Western countries...

Descripción completa

Detalles Bibliográficos
Autores principales: AOKI, Tomokazu, NARITA, Yoshitaka, MISHIMA, Kazuhiko, MATSUTANI, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Neurosurgical Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803700/
https://www.ncbi.nlm.nih.gov/pubmed/33162468
http://dx.doi.org/10.2176/nmc.oa.2020-0243
_version_ 1783635998774657024
author AOKI, Tomokazu
NARITA, Yoshitaka
MISHIMA, Kazuhiko
MATSUTANI, Masao
author_facet AOKI, Tomokazu
NARITA, Yoshitaka
MISHIMA, Kazuhiko
MATSUTANI, Masao
author_sort AOKI, Tomokazu
collection PubMed
description Palliative care and advance care planning (ACP) from the first diagnosis of glioblastoma are important. This questionnaire survey was conducted to understand the current status of palliative care for brain tumors in Japan. Representative characteristics of Japan in comparison with Western countries (P <0.01) are described below: (1) Gender ratio of male in physicians who treat brain tumors in Europe and the United States/Canada are about 70%, but 94% in Japan. (2) The specialty is predominantly neurosurgeon (93%) in Japan. The ratio of neurologists is predominantly 40% in Europe. In the United States/Canada, neurologist (27%) and neurosurgeon (29%) are main parts. (3) Years of medical experience over 15 in physicians is 73% in Japan. Proportions of those with over 15 years are 45% in Europe and 30% in the United States/Canada. (4) In practicing setting, the rate of academic medical centers is about 80% in Europe and the United States/Canada, and ~60% in Japan. Representative differences compared with past domestic data (2007) (P <0.01): (1) In glioblastoma, the rate of explaining about median survival time increases from 39% (2007) to 80% (2018). Explanation about medical conditions to the patient himself with his family increases from 20% (2007) to 39% (2018). (2) Place of death: The rate at hospital is decreasing from 96% (2007) to 79% (2018) and at home is increasing from 3% (2007) to 10% (2018) (3) The rate of ventilator in adult has decreased from 74% (2007) to 54% (2018), but nasal tube feeding has remained unchanged from 62% (2007) to 60% (2018). These results will be shared with physicians to make better care systems for patients with brain tumors.
format Online
Article
Text
id pubmed-7803700
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japan Neurosurgical Society
record_format MEDLINE/PubMed
spelling pubmed-78037002021-01-14 Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan AOKI, Tomokazu NARITA, Yoshitaka MISHIMA, Kazuhiko MATSUTANI, Masao Neurol Med Chir (Tokyo) Original Article Palliative care and advance care planning (ACP) from the first diagnosis of glioblastoma are important. This questionnaire survey was conducted to understand the current status of palliative care for brain tumors in Japan. Representative characteristics of Japan in comparison with Western countries (P <0.01) are described below: (1) Gender ratio of male in physicians who treat brain tumors in Europe and the United States/Canada are about 70%, but 94% in Japan. (2) The specialty is predominantly neurosurgeon (93%) in Japan. The ratio of neurologists is predominantly 40% in Europe. In the United States/Canada, neurologist (27%) and neurosurgeon (29%) are main parts. (3) Years of medical experience over 15 in physicians is 73% in Japan. Proportions of those with over 15 years are 45% in Europe and 30% in the United States/Canada. (4) In practicing setting, the rate of academic medical centers is about 80% in Europe and the United States/Canada, and ~60% in Japan. Representative differences compared with past domestic data (2007) (P <0.01): (1) In glioblastoma, the rate of explaining about median survival time increases from 39% (2007) to 80% (2018). Explanation about medical conditions to the patient himself with his family increases from 20% (2007) to 39% (2018). (2) Place of death: The rate at hospital is decreasing from 96% (2007) to 79% (2018) and at home is increasing from 3% (2007) to 10% (2018) (3) The rate of ventilator in adult has decreased from 74% (2007) to 54% (2018), but nasal tube feeding has remained unchanged from 62% (2007) to 60% (2018). These results will be shared with physicians to make better care systems for patients with brain tumors. The Japan Neurosurgical Society 2020-12 2020-11-06 /pmc/articles/PMC7803700/ /pubmed/33162468 http://dx.doi.org/10.2176/nmc.oa.2020-0243 Text en © 2020 The Japan Neurosurgical Society This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Article
AOKI, Tomokazu
NARITA, Yoshitaka
MISHIMA, Kazuhiko
MATSUTANI, Masao
Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan
title Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan
title_full Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan
title_fullStr Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan
title_full_unstemmed Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan
title_short Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan
title_sort current status of palliative and terminal care for patients with primary malignant brain tumors in japan
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803700/
https://www.ncbi.nlm.nih.gov/pubmed/33162468
http://dx.doi.org/10.2176/nmc.oa.2020-0243
work_keys_str_mv AT aokitomokazu currentstatusofpalliativeandterminalcareforpatientswithprimarymalignantbraintumorsinjapan
AT naritayoshitaka currentstatusofpalliativeandterminalcareforpatientswithprimarymalignantbraintumorsinjapan
AT mishimakazuhiko currentstatusofpalliativeandterminalcareforpatientswithprimarymalignantbraintumorsinjapan
AT matsutanimasao currentstatusofpalliativeandterminalcareforpatientswithprimarymalignantbraintumorsinjapan